Polypeptide constructs including VHH directed against EGFR for intracellular delivery
US9243065B2 · kind B2 · utility
1Cited by
33References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2009 |
| Grant date | Jan 26, 2016 |
| Priority date | — |
| Expiry date | Jul 23, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to polypeptide constructs including VHH directed against EGFR.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.